financetom
Business
financetom
/
Business
/
Update: Major US Pharmacy Benefit Managers Inflated Drug Prices for Over $7.3 Billion Gain, FTC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Major US Pharmacy Benefit Managers Inflated Drug Prices for Over $7.3 Billion Gain, FTC Says
Jan 14, 2025 9:47 AM

12:24 PM EST, 01/14/2025 (MT Newswires) -- (Updates with additional details in the third and fourth paragraphs.)

UnitedHealth Group's ( UNH ) OptumRx, CVS Health's ( CVS ) Caremark Rx and Cigna's ( CI ) Express Scripts marked up a number of specialty generic drugs at their affiliated pharmacies by hundreds or thousands of percent, the US Federal Trade Commission said Tuesday.

The practice allowed the three pharmacy benefit managers and their affiliated specialty pharmacies to generate revenue of more than $7.3 billion from dispensing drugs in excess of their projected acquisition costs from 2017 to 2022, the FTC said.

Citing a second interim staff report on the prescription drug middleman industry, the FTC said the three pharmacy benefit managers got "such significant revenue all while patient, employer, and other health care plan sponsor payments for drugs steadily increased annually."

FTC Chair Lina Khan said the report found that the three pharmacy benefit managers increased costs for various lifesaving drugs, including for heart disease and cancer.

UnitedHealth ( UNH ), CVS and Cigna ( CI ) didn't immediately respond to MT Newswires' requests for comment.

Price: 538.79, Change: -2.36, Percent Change: -0.44

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2025 - www.financetom.com All Rights Reserved